Rapport Therapeutics, Inc. Common StockRAPPNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+181.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+181.0%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
22.2x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$30.31M+37.0%
2024$22.12M+174.2%
2023$8.07M+490.7%
2022$1.37M-